Asgpr-binding compounds for the degradation of extracellular proteins
US-2024424108-A1 · Dec 26, 2024 · US
Modulators of indoleamine 2,3-dioxygenase
US10899754B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10899754-B2 |
| Application number | US-201716464858-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 15, 2017 |
| Priority date | Dec 20, 2016 |
| Publication date | Jan 26, 2021 |
| Grant date | Jan 26, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases such as chronic viral infection, chronic bacterial infections, cancer, sepsis or a neurological disorder.
First claim
Opening claim text (preview).
What is claimed is: 1. The compound or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition comprising a compound or salt thereof according to claim 1 . 3. A method of treating a disease or condition that would benefit from inhibition of IDO1 comprising the step of administration of a composition according to claim 2 to a subject in need thereof, wherein said disease or condition is inflammation associated with HIV infection; chronic viral infections involving hepatitis B virus or hepatitis C virus; cancer; or sepsis. 4. The method of claim 3 wherein in said disease or condition, biomarkers of IDO activity are elevated. 5. The method of claim 3 wherein said biomarkers are plasma kynurenine or the plasma kynurenine/tryptophan ratio.
Assignees
Inventors
Classifications
Nitrogen atoms (nitro radicals C07D237/12) · CPC title
Nitrogen atoms not forming part of a nitro radical · CPC title
condensed with carbocyclic rings or ring systems · CPC title
containing three or more hetero rings · CPC title
One oxygen atom · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10899754B2 cover?
- Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases such as chronic viral infection, chronic bacterial infections, cancer, sepsis or a neurological disorder.
- Who is the assignee on this patent?
- Glaxosmithkline Ip Dev Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07D417/12. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).